Drug intelligence / Profile preview

diethyltoluamide

Development stage
Phase 3
Lead developer
United States Department of Agriculture
Modality
Small Molecules
Administration
Topical
01

Overview

Diethyltoluamide (DEET) is a synthetic chemical compound widely used as the active ingredient in many insect repellent products. It is a slightly yellow oil intended for topical application to skin or clothing and provides protection against mosquitoes, ticks, flies, fleas, chiggers, leeches, and other biting insects. DEET works primarily by interfering with the olfactory receptors of insects—disrupting their ability to detect human scent—though its exact mechanism of action remains not fully elucidated. It is considered one of the most effective and commonly used repellents globally and plays an important role in preventing mosquito- and tick-borne diseases such as malaria, West Nile virus infection, Zika virus infection, Lyme disease, and Rocky Mountain spotted fever[1][2][3][5]. Products containing DEET are available in various formulations including sprays and lotions at concentrations ranging from less than 10% up to 100%[3]. DEET was developed by the United States Army after World War II for use by military personnel in insect-infested areas before becoming available for civilian use. While generally safe when used as directed on skin or clothing surfaces—not under clothing or on broken skin—excessive exposure can cause irritation or rare adverse effects. The mechanism involves disrupting insects' ability to locate humans via their sense of smell rather than killing them directly[1][2][3].

Brand names
OFFRepelCutter
Other names
N,N-diethyl-meta-toluamideDEETdiethyltoluamide
02

Targets

CquiOR136 (Culex quinquefasciatus olfactory receptor 136)Orco (Odorant receptor co-receptor)AgamOBP1 (Anopheles gambiae odorant-binding protein 1)

Beyond the preview

Go deeper on diethyltoluamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on diethyltoluamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call